Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,866 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Hypoxic-Ischemic Encephalopathy, Neonatal Encephalopathy
Interventions: Holding, Saliva collection, No Holding; Behavioral · Other
Lead sponsor: MaineHealth; Other
Eligibility: 24 Hours to 2 Days
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Healthy Adult
Interventions: L-histidine, Monosodium glutamate (MSG), Sodium chloride (NaCl); Dietary Supplement
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis, Chronic Pain, Fatigue
Interventions: Intervention #1, Intervention #2, Intervention #3; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Pain, Back Pain
Interventions: Yoga; Behavioral
Lead sponsor: Robert Saper; Other
Eligibility: 18 Years to 64 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome
Interventions: BL-8040, horse anti-thymocyte globulin (hATG), Methylprednisolone, Cyclosporine; Drug
Lead sponsor: BioLineRx, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Overweight and Obesity
Interventions: Intervention, Control; Behavioral
Lead sponsor: Memorial Hospital of Rhode Island; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Pawtucket, Rhode Island

Conditions: Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell
Interventions: Pegylated Interferon alpha-2b, Capecitabine, 5-FU; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy
Interventions: MAP0004, IV Placebo (Saline), Placebo Inhaler, IV Dihydroergotamine Mesylate (DHE); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ischemic Stroke, Transient Ischemic Attack (TIA), Obstructive Sleep Apnea
Interventions: ASAP Intervention Quality Improvement Protocol; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: West Haven, Connecticut • Indianapolis, Indiana

Conditions: Heart Failure
Interventions: Provider Focus, Patient Interview, PROs/Clinical Data Integration; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 1,033 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Depression
Interventions: Imipramine Pamoate; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteer
Interventions: Alectinib, Esomeprazole, High Fat and Calorie Meal, Standard Meal; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
Interventions: FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF); Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: CHF6001 1600µg, CHF6001 3200µg, Placebo, Roflumilast; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 40 Years and older
Enrollment: 3,973 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 150
States / cities: Andalusia, Alabama • Foley, Alabama • Guntersville, Alabama + 102 more

Conditions: Pain
Interventions: Caldolor, Normal Saline; Drug · Other
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Mobile, Alabama • Little Rock, Arkansas • Arcadia, California + 2 more

Conditions: COVID-19, Olfactory Disorder, Anosmia, Hyposmia, Parosmia
Interventions: Gabapentin gelatin capsules 300mg, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Addiction, Opioid
Interventions: Enhanced Monitoring and Feedback (EMF), NIATx/MAT Academy, NIATx-Internal Facilitation (NIATx-IF), NIATx-External Facilitation (NIATx-EF); Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Olympia, Washington

Conditions: Hiv
Interventions: Data to Suppression (D2S), Usual practice; Other
Lead sponsor: City University of New York; Other
Eligibility: Not listed
Enrollment: 1,494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 27
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: Aripiprazole Lauroxil, Computerized cognitive and functional skills training; Drug · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prostate Cancer
Interventions: Lower-Carbohydrate Med-t-Diet, Low-Fat Med-t-Diet; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Binge Eating Disorder, Bulimia Nervosa
Interventions: Phentermine/Topiramate-First, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Immunoglobulin A Nephropathy
Interventions: sparsentan, irbesartan, Dapagliflozin; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 40
States / cities: Birmingham, Alabama • Homewood, Alabama • Glendale, California + 34 more

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Standard of care; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 78
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more

Conditions: Androgenetic Alopecia
Interventions: PP405 0.05% Topical Gel, Topical Vehicle Gel; Drug
Lead sponsor: Pelage Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Encinitas, California • Thousand Oaks, California • Indianapolis, Indiana + 5 more

Search by objective public record fields.

The Impact of Holding on Stress and Bonding in Mother-Infant Pairs During Therapeutic Hypothermia

Effect of Monosodium Glutamate on Microbiome-Derived Imidazole Propionate Production in Healthy Volunteers

MS Symptom Management Study

Yoga for Chronic Low Back Pain in the Cleveland Clinic Employee Health Plan

Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome

Tailored Lifestyle Intervention in Obese Adults Within Primary Care Practice - Choose to Lose

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

Addressing Sleep Apnea Post-Stroke/TIA

Patient-Reported Outcomes as an Indicator of Disease Transitions in Heart Failure

Bioequivalency Study of Imipramine Pamoate 75 mg Capsules Under Fasted Conditions

A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)

Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients

Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction

Stagewise Implementation-To-Target- Medications for Addiction Treatment (SITT-MAT)

Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program

C-Cog in Early Course Schizophrenia Study

Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer

FDA Approved Medication to Reduce Binge Eating and/or Purging

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

Open Label Study of Long Term Evaluation Against LDL-C Trial

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA